Online inquiry

IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1225MR)

This product GTTS-WQ1225MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TPBG gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Non-small lung carcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001166392.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7162
UniProt ID Q13641
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1225MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11408MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ11133MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ5601MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ3363MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ13969MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ15931MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ4226MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ15316MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW